FRMD3

Across TCGA pan-cancer cohorts, FRMD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FRMD3 data layer compared with 18 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FRMD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FRMD3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where FRMD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.895	0.589	<.001	72	view →
LUAD	OS	Quartile	III,IV	0.708	1.000	.040	6	view →
LSCC	DFS	Tertile	All	0.666	0.371	.038	4	view →
GBM	DFS	Quartile	All	0.197	0.413	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FRMD3–CCRCC (DFS)

Open the CCRCC breakdown →